WHI 2022 STEERING COMMITTEE
WHY ATTEND?
Now in its 4th year, the Women’s Health Innovation Summit is the sector’s premier platform showcasing the most exciting investment opportunities globally and connecting businesses with investors, strategic corporate partners, and critical women’s health collaborators. Our mission is to engage all key participants in the value chain so we can continue to play our role in accelerating the industry to improve the outcomes, access, and quality of health care for women worldwide.
Following the industry’s growth, and our goal to address both women specific indications and needs, as well as areas that predominantly or differently affect women, our program this year will seek to address the full extent of this ever-evolving market through a 2 tracked event.
We are excited to be providing insight into the business challenges and investment opportunities, from conception through to commercialization and exit with start-ups, as well as deep diving into creating solutions for the most critical areas of women’s health, with highest morbidity and mortality.
Join us for two days of exceptional learning and collaboration; witness incredible innovation and start-ups through our industry-renowned showcase; and meet a network of individuals dedicated to the growth of this sector in one place.
Be part of the innovation story in women’s health, and attend alongside our leading network of, biotech’s, start-ups, Femtech, insurers, CRO’s, investors, medical device companies, researchers, pharmaceuticals, HCP’s and advocacy groups, to drive innovation at the convergence of healthcare and technology.
Women's Health Series Past Attendees
FREE TO ATTEND WEBINAR
2022 Partners
Bespoke Partner
GSK
Website: https://www.gsk.com/en-gb/
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us
Platinum Partners
Organon
Website: https://www.organon.com/
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, N.J.
Gold Partners
Sagentia Innovation
Website: www.sagentiainnovation.com
Sagentia Innovation provides independent advisory and leading-edge product development services focused on science and technology initiatives. Working across the medical, industrial, chemicals and energy, food and beverage, and consumer sectors, Sagentia Innovation works with a broad range of companies from some of the world’s leading and best-known brands, to start-up disruptors, new to the market. It is part of Science Group (AIM:SAG), which has more than ten offices globally, two UK-based dedicated R&D innovation centres and more than 400 employees. Other Science Group companies include Leatherhead Food Research, TSG Consulting and Frontier Smart Technologies.
Event Partners
Celanese
Website: https://bit.ly/3a0JriQ
Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our VitalDose® EVA copolymer drug-delivery platform is an enabling technology for drug-eluting implants, inserts and transdermal films. The platform is flexible and customizable to address a variety of formulation challenges when it comes to tailoring the release rate of your drug.
- Compatible with biologics and small molecules
- Provides reliable local or systemic drug administration
- High drug loading capacity (≤ 75%)
- Engineered long-acting dosage profiles (zero-order or nonlinear profiles)
- Ease of formulation and configurable into a variety of geometries
- An established regulatory path with long clinical use history
From FEASIBILITY to DEVELOPMENT to COMMERCIALIZATION
Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support.
Watkins-Conti Products Inc
Website: http://www.watkinscontiproducts.com/
Watkins Conti Products, Inc. is a Female founded and owned, Platform Women’s Healthcare company and product design firm that is focused on the creation of innovative and affordable consumer medical devices.
The company’s flagship product is a non-invasive solution for stress incontinence in women. The problem impacts and estimated ONE in THREE women globally. The disruptive, patented product offers multiple recurring revenue streams. Watkins-Conti has additional products in the pipeline to improve the consumer experience, specifically for health related issues that women face that are often seen as shameful or taboo.
AUDIENCE BREAKDOWN
Previous Speakers Include
Alice Zheng, MD, MBA, MPH
Kathryn G. Schubert, MPP
Marsha B. Henderson
Marsha B. Henderson is a nationally recognized innovative leader and change agent for the health of women and their families. As the former Associate Commissioner for Women’s Health at the Food and Drug Administration, for a decade, she progressed and managed cutting-edge policy, research and educational outreach initiatives. The Office of Women’s Health advanced its scientific efforts, under her direction, to produce more than 350 research papers and journal articles to facilitate FDA’s regulatory decision-making and promote a better understanding of sex differences and health conditions unique to women. Her tenure produced the first FDA Women’s’ Health Research Roadmap, outlining seven priority areas for new or enhanced research including biomarkers, nanotechnology, cardiovascular disease, and postmarket surveillance as well as a framework to assess its impact. Her colleagues applaud her ability to set a vision and guide the concept to reality. One FDA Commissioner stated, “She is elegant…not just in style but in character, confidence and compassion.”
Ms. Henderson’s expertise in the development of public-private partnerships and culturally appropriate consumer engagement strategies led to the Women’s Health Take Time To Care Program, which has reached over 120 million people with FDA consumer information in 18 languages, and received awards from more than 96 national organizations. Her easy to read, science-based materials have been chronicled in Dear Abby, Parade Magazine, Hints from Heloise, and the IRS, as well as sponsored by external groups including the National Association of Chain Drug Stores, American Diabetes Association, Ford Motor Company, American Medical Association, and even Las Vegas casinos. Her novel efforts supported a one-stop Pregnancy Exposure Registries website to gather information about how prescription drugs or vaccines affect a pregnant woman and her fetus. In addition, she recently instructed her staff to expand the Science of Sex and Gender on-line accredited courses with the NIH/Office of Research on Women’s Health and to conduct FDA’s first “Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender” to address this national epidemic.
She is the recipient of numerous awards including the Dr. Estelle Ramey Award for Women’s Health Leadership from Society for Women’s Health Research; “HerMANA” Award for innovative outreach to Hispanic women, and Pinnacle Award for exceptional leadership in medication use for patients and caregivers. The first non-pharmacist to receive the prestigious Jacob Miller Award from the American Pharmacists Association Foundation, she was also one of five Samuel J. Heyman Service to America Medal (Sammies) finalists from throughout the U.S. federal government. And as Chair of the national board of the YWCA USA, she led the U.S. delegation at the YWCA World Council quadrennial meeting in Bangkok, Thailand to focus on women’s issues.
Prior to her FDA career, Ms. Henderson served as the Director of Evaluation for the Interagency Council on the Homeless; Director of Placement for the National Health Service Corps; Chief of Analysis and Information for the Bureau of Maternal and Child Health; and Senior Advisor to the Director of the Women's Bureau at the U.S. Department of Labor. Ms. Henderson earned a master’s degree from Rutgers University in health and hospital planning. She is married to Wade Henderson, an internationally renowned civil and human rights lawyer.
Dr. Sandy Milligan
Beth Battaglino
Dr. Nieca Goldberg
Tracy Warren
Erica Kantor
Elizabeth Bailey
Jamie White
Deirdre Albertson
Lauren Demosthenes
Georgie Kovacs
Juan Camilo Arjona Ferreira
Missy Lavender
Susan Trent
Susan Trent, CEO, joined Atlantic Therapeutics in December 2019, leading the successful DTC launch of INNOVO® in the US and quickly demonstrating the scale-up potential of the brand. Prior to Atlantic Therapeutics, Susan spent 20+ years at GSK, building deep Pharmaceutical and Consumer Healthcare experience including the switch and transformation of Rx products into high-growth direct-to-consumer brands in weight control, smoking control, and skincare. Multi-market General Management, Marketing and BD leadership roles across Europe, US and Asia.
Reenita Das
Eric Dy
Farida Peters-Abbadi
Omar Dawood
Liz Klinger
Rachel Braun Scherl
Marta Hill Gray
Nathanial DeNicola
Tania Small
Ally Crays
Rich Jones
Michela Bedard
Maggie Perracchio
Nicole Leeds
Jannine Versi
Allison Conti
Kelle Moley, MD
Dr. Kelle Moley is a career physician-scientist obstetrician/gynecologist who currently leads the Reproductive Health Technologies Domain within the Discovery & Translational Sciences, Global Health Division at the Bill and Melinda Gates Foundation. Kelle joined BMGF in July 2020, with a 30-year history of basic and translational research on reproductive health issues in females throughout the life course-- from organismal to cellular and molecular levels of metabolic, developmental biology, embryo implantation and decidualization, and infectious diseases of the female reproductive tract.
Kelle earned her BA from Wellesley College, and her MD from Yale Medical School. Thereafter, she pursued an Obstetrics & Gynecology Residency and a Fellowship in Reproductive Endocrinology & Fertility at Washington University in St. Louis School of Medicine. Kelle then spent the next 3 decades of a thriving research career at Washington University—rising to become the James P. Crane Professor of Obstetrics & Gynecology, Vice Chair of Obstetrics & Gynecology, Chief of the Division of Basic & Translational Research for the Department of Obstetrics & Gynecology, Co-Director of the Institute of Clinical & Translational Science for the School of Medicine, and Director of the Center for Reproductive Health Sciences at the School of Medicine. Her research (published in some 150 peer-reviewed primary articles) led to an international reputation along with numerous honors, including election to the National Academy of Medicine in 2014. She also earned a reputation as a superb mentor to trainees, leading the reproductive endocrinology fellowship program at Washington University until she left academia in 2018. After a 2-year stint as Chief Scientific Officer and Senior Vice President of the March of Dimes she left to pursue her new position at BMGF.
Dr Dan Martin
Dr. Dan Martin is the Scientific and Medical Director of the Endometriosis Foundation of America (www.EndoFound.org). He has studied endometriosis since 1970 with endometriosis publications beginning in 1983.
He is a community member of the Virginia Commonwealth University Institutional Review Board, Professor Emeritus of the University of Tennessee Health Science Center, and a life fellow of the American College of Obstetricians and Gynecologists. Dr. Martin is on the editorial boards of three medical journals. He has been Divisional Director of Reproductive Endocrinology and Divisional Director of Minimally Invasive Surgery at the University of Tennessee Health Science Center and Divisional Director of Medical Education at The Johns Hopkins Medical Institutes. He is a Past President of the American Association of Gynecologic Laparoscopists and the Gynecologic Laser Society.
Lucy Perez, PhD
Tanika Gray Valbrun
Elizabeth Garner
Sabrina Martucci Johnson
Sabrina Martucci Johnson is a life sciences executive with a record of achievement in building successful companies, launching innovative products into specialty markets, delivering returns on shareholder investments, and implementing complex directional change.
Sabrina is committed to advancing innovation in women’s health. She is the Founder and CEO of DARÉ Bioscience (NASDAQ:DARE), a clinical-stage biopharmaceutical company driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. Prior to founding DARÉ, Sabrina was President of WomanCare Global Trading, a global provider of women’s health products, CFO/CAO of the California Institute for Biomedical Research, CFO/COO of Cypress Bioscience, Inc. (NASDAQ:CYPB), held marketing and sales positions with Advanced Tissue Sciences, and began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on the recombinant factor VIII program.
Sabrina has a Master of International Management with honors from the American Graduate School of International Management (Thunderbird); a MSc. in Biochemical Engineering from the University of London, University College London; and a BSc. in Biomedical Engineering from Tulane University, magna cum laude.
Sabrina currently serves on the boards of ATAI Life Sciences, a publicly-traded clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and Aethlon Medical, Inc., a publicly-traded company developing immunotherapeutic technologies to combat infectious disease and cancer, BIOCOM, as Vice President of Industry, the Clearity Foundation as Chair, and the YWCA of San Diego County as Past President. Additionally, Sabrina serves on the Board of Advisors of Tulane University School of Science & Engineering and on the Audit Committee of Project Concern International.
Ms. Johnson was honored by Athena, a San Diego-based business organization championing women executives and rising managers in science, technology, engineering and mathematics, with the Individual in Life Science award in 2017 and the same year received the “Moxie” for her grit and determination and positive impact in the community from the award-winning MOXIE Theatre, a Southern California theatre dedicated to producing diverse and honest images of women using the art of theatre. She was an E&Y Entrepreneur of the Year San Diego finalist in 2018 and in 2019 was recognized as an entrepreneur in the PharmaVoice 100 and honored as 2019 Director of the Year in the Emerging Board Leader category by the San Diego Corporate Directors Forum.
Jennifer Stearns
Tina Ripperger
Maria Velissaris
Jessica Federer
Anula Jayasuriya
Kalahn Taylor-Clark, PhD MPH
Anula Jayasuriya
Linda Dunbar
Barb Collura
Delphine O'Rourke
Valerie Palmieri
LESLEY NORTHROP, PH.D., DABMGG, FACMG
Brittany Barreto
Sasha Ottey, MHA, MT, (ASCP)
Chris Jackson
Jessica Hatheway
Mylene Yao
Charmain F. Jackman, PhD
Marta Hill Gray
Dr. Neel Shah
Stephen Palmer, PhD
Cheryl Kerr
Primavera Spagnolo, MD, PhD
Download 2021 agenda
Please complete the form to access the 2021 Women's Health Innovation Summit (WHIS) Agenda.
“This summit is a wonderful opportunity to learn about exciting innovations on the horizon and connect with potential collaborators in Women's Health.” Allison Conti, Watkins-Conti Products
View our agenda for the Women's Health Innovation Summit 2021
Become a Partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
REGISTRATION
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
TICKET PRICES INCREASE IN
Returning Safely Measures
Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.
All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.
Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.